Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in:

16.05.2023 | Gynecologic Oncology

Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study

verfasst von: Ronalds Macuks, Yusuf Yildirim, Rosanna Mancari, Patriciu Achimas-Cadariu, Thumuluru K. Madhuri, Eugenia Ortega, Michael Mallmann, Oliver Zivanovic, Ignacio Zapardiel, SARCUT Study Group

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to analyze the prognostic factors related to the recurrence rate and overall survival of patients with undifferentiated uterine sarcoma.

Methods

An international multicenter study involving 43 international centers, the SARCUT study, collected 966 uterine sarcoma cases; among them 39 cases corresponded to undifferentiated uterine sarcoma and where included in the present subanalysis. The risk factors related to the oncological outcomes where analyzed.

Results

The median age of the patients was 63 (range 14–85) years. Seventeen (43.5%) patients presented FIGO stage I. The 5-year overall survival (OS) was 15.3% and 12-months disease-free survival (DFS) 41%. FIGO stage I was significantly associated with a better prognosis. In addition, patients who received adjuvant radiotherapy showed significant longer disease-free survival compared to those without adjuvant radiotherapy (20.5 vs. 4.0 months, respectively; p = 0.04) and longer overall survival (34.7 vs. 18.2 months, respectively; p = 0.05). Chemotherapy administration was associated with shorter DFS (HR 4.41, 95% CI 1.35–14.43, p = 0.014). Persistent disease after primary treatment (HR = 6.86, 95% CI 1.51–31.09, p = 0.012) and FIGO stage IV (HR 4.12, 95%CI 1.37–12.44, p = 0.011) showed significant worse prognosis for OS.

Conclusion

FIGO stage seems to be the most important prognostic factor in patients with undifferentiated uterine sarcoma. Adjuvant radiotherapy seems to be significantly associated also to a better disease-free and overall survival. On the contrary, the role of chemotherapy administration remains unclear since was associated to a shorted DFS.
Literatur
1.
Seagle B-LL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S (2017) Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 145(1):61–70PubMed
2.
Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B (2016) Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer 26(6):1098–1104PubMed
3.
Nordal RR, Thoresen SO (1997) Uterine sarcomas in Norway 1956–1992: Incidence, survival and mortality. Eur J Cancer 33:907–911PubMed
4.
Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 119:2922–2930PubMed
5.
Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009) Uterine sarcomas in norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364PubMed
6.
Oliva E (2014) Cellular mesenchymal tumors of the uterus: A review emphasizing recent observations. Int J Gynecol Pathol 33:374–384PubMed
7.
Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E et al (2008) Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32:1228–1238PubMed
8.
Gil-Benso R, Lopez-Gines C, Navarro S, Carda C, Llombart-Bosch A (1999) Endometrial stromal sarcomas: immunohistochemical, electron microscopical and cytogenetic findings in two cases. Virchows Arch 434:307–314PubMed
9.
Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H et al (2001) Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 98:6348–6353PubMedPubMedCentral
10.
Croce S, Hostein I, Ribeiro A, Garbay D, Velasco V, Stoeckle E et al (2013) YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations. Mod Pathol 26:1390–1400PubMed
11.
Sciallis AP, Bedroske PP, Schoolmeester JK, Sukov WR, Keeny GL, Hodge JC et al (2014) High-grade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. Am J Surg Pathol 38:1161–1172PubMed
12.
Hoang LN, Aneja A, Conlon N, Delair DF, Middha S, Benayed R et al (2017) Novel high-grade endometrial stromal sarcoma: a morphologic mimicker of myxoid leiomyosarcoma. Am J Surg Pathol 41:12–24PubMedPubMedCentral
13.
Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollman TJ et al (2018) ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Mod Pathol 31:674–684PubMed
14.
Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhomme C et al (2000) Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88:1425–1431PubMed
15.
Leath CA, Huh W, Hyde J, Cohn DE, Resnick KE, Taylor NP et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630–634PubMed
16.
Chan JK, Kawar NM, Shin JY, Osann K, Chen L, Powell CB et al (2008) Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210–1215PubMedPubMedCentral
17.
D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116:131–139PubMed
18.
Feng W, Malpica A, Robboy SJ, Gudlaugsson E, Hua K, Zhou X et al (2013) Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. Int J Gynecol Pathol 32:299–306PubMed
19.
Feng W, Hua K, Malpica A, Zhou X, Baak JP (2013) Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough? Int J Gynecol Cancer 23:488–493PubMed
20.
Nucci MR, Harburger D, Koontz J, Dal Cin P, Sklar J (2007) Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol 31:65–70PubMed
21.
Gremel G, Liew M, Hamzei F, Hardell E, Selling J, Ghaderi M et al (2015) A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer 136:1608–1618PubMed
22.
Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH et al (2017) Validation of a mitotic index cutoff as a prognostic marker in undifferentiated uterine sarcomas. Am J Surg Pathol 41:1231–1237PubMed
23.
Malouf GG, Lhommé C, Duvillard P, Morice P, Haie-Meder C, Pautier P (2013) Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynaecol Obstet 122:57–61PubMed
24.
Yim GW, Nam EJ, Kim SW, Kim YT (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104(3):177–178
25.
Zapardiel I, Morrow CP (2011) New terminology for cytoreduction in advanced ovarian cancer. Lancet Oncol 12(3):214PubMed
26.
Meurer M, Floquet A, Ray-Coquard I, Bertucci F, Auriche M, Cordoba A et al (2019) Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. Int J Gynecol Cancer 29(4):691–698PubMed
27.
Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML (2012) High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 127:27–31PubMed
28.
Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S et al (2012) Outcome and prognostic factors in endometrial stromal tumors: a rare cancer network study. Int J Radiat Oncol Biol Phys 82:e757-763PubMed
29.
Zaloudek C, Hendrickson MR, Soslow RA (2011) Mesenchymal tumors of the uterus. In: Kurman RJ, WEllenson LH, Ronnett BM (Hrsg) Blaustein’s pathology of the female genital tract, 6. Aufl. Springer, New York, 453–578
30.
Nagai T, Takai Y, Akahori T, Ishida H, Hanaoka T, Uotani T et al (2014) Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass. Springerplus 3:678PubMedPubMedCentral
31.
Samuel A, Fennessy FM, Tempany CM, Stewart EA (2008) Avoiding treatment of leiomyosarcomas: the role of magnetic resonance in focused ultrasound surgery. Fertil Steril 90:e9-12
32.
Parker WH, Fu YS, Berek JS (1994) Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83:414–418PubMed
33.
Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW et al (2013) The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer 108(3):727–734PubMedPubMedCentral
34.
Kennedy MM, Baigrie CF, Manek S (1999) Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and nonYHRT-related endometrial pathology. Int J Gynecol Pathol 18:130–137PubMed
35.
Rauh-Hain JA, del Carmen MG (2013) Endometrial stromal sarcoma: a systematic review. Obstet Gynecol 122(3):676–683PubMed
36.
Garg G, Shah JP, Toy EP, Bryant CS, Kumar S, Morris RT (2010) Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol 118:8–13PubMed
37.
Gadducci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129–142PubMed
38.
Ríos I, Rovirosa A, Morales J, Gonzalez-Farre B, Arenas M, Ordi J et al (2014) Undifferentiated uterine sarcoma: a rare, not well known and aggressive disease: report of 13 cases. Arch Gynecol Obstet 290:993–997PubMed
39.
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S et al (2008) Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for research and treatment of cancer gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818PubMed
40.
Gremel G, Liew M, Hamzei F, Hardell E, Selling J, Ghaderi M et al (2015) A prognosis-based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer 136:1608–1618PubMed
41.
Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016) Progesterone receptor expression is an independent prognosticator in FIGO Stage I uterine leiomyosarcoma. Am J Clin Pathol 145:449–458PubMed
42.
Huss A, Klar M, Hasanov MF, Juhasz-Böss I, Bossart M (2023) Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. Arch Gynecol Obstet 307(3):927–935PubMed
Metadaten
Titel
Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study
verfasst von
Ronalds Macuks
Yusuf Yildirim
Rosanna Mancari
Patriciu Achimas-Cadariu
Thumuluru K. Madhuri
Eugenia Ortega
Michael Mallmann
Oliver Zivanovic
Ignacio Zapardiel
SARCUT Study Group
Publikationsdatum
16.05.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2023
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-07057-x

Weitere Artikel der Ausgabe 3/2023

Caprini assessment utilization and impact on patient safety in gynecologic surgery

  • General Gynecology

A systematic review of the impact of 7-keto-DHEA on body weight

  • Open Access
  • Review

Clinical evaluation of a new hand-driven hysteroscopic tissue removal device, Resectr™ 5fr, for the resection of endometrial polyps in an office setting

  • General Gynecology

Association of embryo aneuploidy and sperm DNA damage in unexplained recurrent implantation failure patients under NGS-based PGT-A cycles

  • Gynecologic Endocrinology and Reproductive Medicine

Effects of gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in artificial cycles: a meta-analysis

  • Review

Could uterine conservation be an option in presumed early-stage epithelial ovarian cancer?

  • Gynecologic Oncology

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Brustkrebstherapie: zu wenig Aufklärung über Nebenwirkungen?

Ergebnisse eines internationalen Surveys legen nahe, dass die Aufklärung über Nebenwirkungen einer Brustkrebstherapie häufig unzureichend ausfällt bzw. zu spät erfolgt.

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

VTE-Risiko auch unter aktuellen Hormonkontrazeptiva erhöht

Registerdaten aus Dänemark helfen dabei, das Risiko für venöse Thromboembolien (VTE) unter verschiedenen aktuellen Verfahren zur hormonellen Verhütung einzuschätzen. Verhältnismäßig hoch ist es demnach unter Kombi-Pillen mit Drittgenerations-Gestagenen.  

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise